Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 29, 2009

Hypertension. 2009
Published online before print June 29, 2009, doi: 10.1161/HYPERTENSIONAHA.109.133892
A more recent version of this article appeared on August 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
54/2/315    most recent
HYPERTENSIONAHA.109.133892v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Krop, M.
Right arrow Articles by Jan Danser, A. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krop, M.
Right arrow Articles by Jan Danser, A. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Biochemistry and metabolism
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease

Submitted on April 2, 2009
Revised on April 26, 2009

Cardiac Renin Levels Are Not Influenced by the Amount of Resident Mast Cells

Manne Krop; Richard van Veghel; Ingrid M. Garrelds; René J.A. de Bruin; Jeanette M.G. van Gool; Anton H. van den Meiracker; Marco Thio; Paul L.A. van Daele; and A. H. Jan Danser*

From the Divisions of Pharmacology, Vascular and Metabolic Diseases (M.K., R.v.V., I.M.G., R.J.A.d.B., J.M.G.v.G., A.H.v.d.M., A.H.J.D.) and Immunology (P.L.A.v.D.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Section of Pharmacology and Pathophysiology (M.T.), Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

* To whom correspondence should be addressed. E-mail: a.danser{at}erasmusmc.nl.

Abstract—To investigate whether mast cells release renin in the heart, we studied renin and prorenin synthesis by such cells, using the human mast cell lines human mastocytoma 1 and LAD2, as well as fresh mast cells from mastocytosis patients. We also quantified the contribution of mast cells to cardiac renin levels in control and infarcted rat hearts. Human mastocytoma 1 cells contained and released angiotensin I–generating activity, and the inhibition of this activity by the renin inhibitor aliskiren was comparable to that of recombinant human renin. Prorenin activation with trypsin increased angiotensin I–generating activity in the medium only, suggesting release but not storage of prorenin. The adenylyl cyclase activator forskolin, the cAMP analogue 8-db-cAMP, and the degranulator compound 48/80 increased renin release without affecting prorenin. Angiotensin II blocked the forskolin-induced renin release. Angiotensin I–generating activity was undetectable in LAD2 cells and fresh mast cells. Nonperfused rat hearts contained angiotensin I–generating activity, and aliskiren blocked {approx}70% of this activity. A 30-minute buffer perfusion washed away >70% of the aliskiren-inhibitable angiotensin I–generating activity. Prolonged buffer perfusion or compound 48/80 did not decrease cardiac angiotensin I–generating activity further or induce angiotensin I–generating activity release in the perfusion buffer. Results in infarcted hearts were identical, despite the increased mast cell number in such hearts. In conclusion, human mastocytoma 1 cells release renin and prorenin, and the regulation of this release resembles that of renal renin. However, this is not a uniform property of all mast cells. Mast cells appear an unlikely source of renin in the heart, both under normal and pathophysiological conditions.


Key words: renin • prorenin • mast cell • heart • cAMP